Metabolism - Clinical and Experimental
Volume 54, Issue 5, Supplement , Pages 5-9 , May 2005

Overview of the field

  • Jorge Alberto Costa e Silva

      Affiliations

    • Corresponding Author InformationThe International Center for Mental Health Policy and Research, New York University-School of Medicine, New York, NY, USA. Tel.: +1 212 263 3902; fax: +1 212 2421 5406.
    • Tel.: +55 21 2539 2196; fax: +55 21 2266 5248.

References 

  1. Seva A. In: The European handbook of psychiatry and mental health. vol. 1:Barcelona: Editorial Antropos Promat. S. Coop Ltda; 1991;p. 859–865
  2. Kraepelin E. Manic depressive insanity and paranoia. Edinburgh: E & S Livingstone; 1921;
  3. Bleuler E. Textbook of psychiatry. New York: Dover; 1951;
  4. Tellenbach H. Psychopathologie Der Cyclothymic Nervenartz. 1977;48:335
  5. Leonhard K. Aulteilung der endogenen psychosen. Berlin: Akademie Verlag; 1951;
  6. World Health Organization. The World Health Report 2001—Mental Health: New understanding. Geneve: WHO; 2001;
  7. Lesperance F, Frasure-Smith N. Depression in patients with cardiac disease: a practical review. J Psychosom Res. 2000;48:379–391
  8. Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in addicts with diabetes: an epidemiological evaluation. Diabetes Care. 1993;16:1167–1178
  9. Keller MB, Hirschfeld RM, Hanks D. Double depression: a distinctive subtype of unipolar depression. J Affect Disord. 1997;45:65–73
  10. Angst J. How recurrent and predictable is depression illness?. In:  Montgomery SA,  Rouillon F editor. Long-term treatment in depression. New York (NY): John Willey; 1922;p. 29–39
  11. Lavori PW, Keller MB, Schettner W, Fawcett J, Mueller J, Mueller TI. Recurrence after recovery in unipolar MDD. An observational follow-up of clinical predictions and somatic treatment as a mediating factor. Int J Methods Psychiatr Res. 1994;4:211–229
  12. Anhst J. Depression and anxiety: implications for nosology, course, and treatment. J Clin Psychiatry. 1997;58(Suppl. 8):3–5
  13. Merikangas KR, Angst J, Eaton W, et al. Comorbidity and boundaries of affective disorders with anxiety disorders and substance misuse: results of an international task force. Br J Psychiatry. 1997;(Suppl.):58–67
  14. Murray CJ, Lopez AD, Jamison DI. The global burden of disease in 1990: summary results, sensitivity analyses and future directions. Bull World Health Organ. 1994;72:495–509
  15. Dreverts WC. Neuroimaging studies of mood disorders. Biol Psychiatry. 2000;48:813–829
  16. Baumann B, Danos P, Krell D, et al. Reduced volume of limbic system-affiliated basal ganglia in mood disorders: preliminary data from a postmortem study. J Neuropsychiatry Clin Neurosci. 1999;11(1):71–78
  17. Sheline YI. 3D MRI studies of neuroanatomic changes in unipolar major depressions: the role of stress and medical comorbidity. Biol Psychiatry. 2000;48:791–800
  18. McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci. 1999;22:105–122
  19. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res. 2000;886:172–189
  20. Malberg J, Eisch AJ, Netler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult hippocampus. J Neurosci. 2000;20:9104
  21. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999;45:1085–1098
  22. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A. 1998;95:13290–13295
  23. Bremner J, Narayan M, Anderson ER, Staib LH, Miller H, Charney DS. Smaller hippocampal volume in major depression. Am J Psychiatry. 2000;157:115–117
  24. Czeh B, Michaelis T, Watanable T, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A. 2001;98:12796–12801
  25. Berrettini W. Molecular linkage studies in bipolar disorder. Dialogues Clin Neurosci. 1999;1:12–21
  26. Craddock N, Khodel V, Van Eerdewegh P, Reich T. Mathematical limits of multilocus models: the genetic transmission of bipolar disorder. Am J Hum Genet. 1995;57:690–702
  27. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry. 1995;100:2941–2947
  28. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment-resistant depression. Cytokine. 1997;9:853–858
  29. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav. 1997;56:131–137
  30. Rosenbaum JF, Fava M, Niermberg A. The pharmacologic treatment of mood disorders. Psychiatr Clin North Am. 1994;1:17–50
  31. Costa e Silva JA. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1998;59(7):352–357
  32. Goa KL, Wald A. Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs. 1986;32:114–129
  33. Schatzberg AF, Cole JO. In: Manual of clinical psychopharmacology. Washington, DC: American Psychiatric Press, Inc.; 1986;p. 167–168
  34. Costa e Silva JA, Nadelson CC. In: International review of psychiatry. vol. I:American Psychiatric Press Inc.; 1993;p. 139–160

PII: S0026-0495(05)00027-2

doi: 10.1016/j.metabol.2005.01.005

Metabolism - Clinical and Experimental
Volume 54, Issue 5, Supplement , Pages 5-9 , May 2005

Article Tools